News Releases
In this section
-
Mar 7, 2018
BRIDGEWATER, N.J., March 07, 2018 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today...
-
Feb 23, 2018On track to file NDA before the end of March and anticipate a priority review
BRIDGEWATER, N.J., Feb. 23, 2018 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today reported...
-
Feb 21, 2018
BRIDGEWATER, N.J., Feb. 21, 2018 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today...
-
Feb 20, 2018
BRIDGEWATER, N.J., Feb. 20, 2018 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today...
-
Feb 15, 2018
BRIDGEWATER, N.J., Feb. 15, 2018 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today...
-
Feb 7, 2018
BRIDGEWATER, N.J., Feb. 07, 2018 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today...
-
Jan 26, 2018
BRIDGEWATER, N.J., Jan. 26, 2018 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM) announced the closing today of its previously announced public offering of its 1.75% convertible senior notes...
-
Jan 24, 2018
BRIDGEWATER, N.J., Jan. 24, 2018 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today...
-
Jan 23, 2018
BRIDGEWATER, N.J., Jan. 23, 2018 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM) announced today that it priced its registered underwritten public offering of $400 millionaggregate principal...
-
Jan 22, 2018
BRIDGEWATER, N.J., Jan. 22, 2018 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM) announced today that it has commenced an underwritten public offering of $300 millionaggregate principal...
Contact Us
